Liver Affection in Pregnant Women at Sohag University Hospital
ConditionLiver Biomarkers
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-50
SponsorEman Ashraf Saad Ahmed
About this trial
This study investigates the prevalence, causes, and clinical outcomes of liver disorders among pregnant women attending Sohag University Hospital. It aims to identify the most common hepatic conditions occurring during pregnancy, evaluate their impact on maternal and fetal health, and assess the effectiveness of current diagnostic and management approaches. By analyzing clinical data, laboratory findings, and pregnancy outcomes, the study highlights the importance of early detection and proper management of liver diseases to reduce associated complications and improve overall maternal-fetal prognosis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
The study population includes pregnant women attending Sohag University Hospital during the study period. Participants are women of reproductive age with a confirmed pregnancy who are diagnosed with the targeted liver disorder. Inclusion is irrespective of gestational age at diagnosis, while women with pre-existing chronic liver failure or other severe systemic illnesses are excluded. The study focuses exclusively on female participants
Trial design
Design model
Other
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
80 Participants
are grouped into 1 trial groupGroup A: all pregnant women attending sohag university hospitals for liver disease assessment
Trial outcomes
Primary outcomes
1
Change in liver disease severity index
Change from baseline in a standardized liver disease severity index combining biochemical and clinical measures in pregnant women. The index is computed using: serum ALT (IU/L), AST (IU/L), total bilirubin (mg/dL), albumin (g/dL), INR, and a short clinical symptom score (pruritus, jaundice, abdominal pain). Outcomes reported as absolute change and percent change in the composite score to evaluate progression or improvement of the liver disorder.
Time frame
from baseline up to deliveryLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Eman Ashraf Saad Ahmed
Lead sponsor
Sohag University
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: